Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So when do you think the ACTIV-5 data will be available to the FDA?
I picked up some VIX calls today as well.
I think so too. Chappell was previously selling 3 days a week. In Aug, he has cut back to 2 days a week (when the price is > 17). Hopefully, he'll be done in 2 or 3 more weeks.
Be taken down on what grounds? There is nothing illicit about this.
No selling from Chappelle's 10b5-1 last week. Looks like a confirmation that it only sells when the price is higher than $17.
The shit is gonna really hit the fan after the schools and colleges start in-person learning again in a few weeks. And there will be a 30 minute superspreader event every school day... lunch time. The summer camps gave us a bit of a preview on what will happen.
Nice one!
The numbers I cited are from Fintel.
https://fintel.io/n/us/hgen/chappell-dale
Chappell acquired 32 million shares at 0.0937 per share in Feb 2018. $HGEN price is currently $16, which is 170x what he paid for it. He is already sitting on humongous gains, so why not take some off the table?
You're absolutely right. The sales were on Wednesday and Thursday. Too early in the morning when I wrote that!
Chappelle's 10b5-1 sold another 39,086 shares on Thursday and Friday this week. The good news is that the plan seems to have a floor of $17, below which it stops selling.
https://fintel.io/n/us/hgen/chappell-dale
The PR triggered a 120k volume spike when it was released. Made the algos go nuts. Lol
Yes, this is a great level to add more shares at. I am already sitting on a boatload of shares though. I suspect if the 10b5-1 keeps selling in the first week of August, it'll just keep going for the rest of the month.
Fintel says Chappell's sales up to June 18 were not part of an automatic trading plan.
On a closer look at Chappell's transactions, he has sold shares every single week since the beginning of June. The total number of shares sold is 3,628,716. That comes out to an average of 450k shares per week.
By my calculation, Chappell owned 23% of the company at the beginning of June. After unloading all these shares, he is down to 17%. Hopefully, he will stop at 15%. If he is aiming for 10% instead, we are in for some more choppy waters, mis amigos.
I had previously posted on Twitter that all this selling was just noise, like the heavy selling by $MRNA insiders last year. I hope that is still the case, but I am wondering more now why all this selling with the EUA approval just around the corner.
One nugget that I was able to glean from analyzing Chappell's transactions week by week is that the selling occurs most often in the second half of each week.
#sales
M: 1
Tu: 0
W: 5
Th: 5
F: 6
So if he continues true to form, then Friday is the best day for anyone looking to pick up more shares.
But hopefully, the EUA approval will come next week and none of this will matter anymore.
Chappell torpedoed the stock the past 3 days by selling 316,353 more shares. Is he trying to get down to the 15% ownership mark?
https://fintel.io/n/us/hgen/chappell-dale?utm_source=Twitter&utm_medium=Social&utm_campaign=insider
UK uses mostly Astra Zenica with some Pfizer.
"Sure they didn’t say moving to a phase 3 trial? I don’t think they would move it into activ-3"
Cliff Lane, NIAID Deputy Director for Clinical Research and Special Projects, talks about moving from ACTIV-5 to ACTIV-3 at about the 2 hr 37 min mark in the replay of the NIH webcast from Thursday.
https://videocast.nih.gov/watch=42269
Not so fast. LIVE-AIR (the Ph3 trial) was Lenzilumab + SOC (remdesivir and/or dexamethasone) vs placebo + SOC. ACTIV-5 is Lenz + remdesivir vs placebo + remdesivir. The two trials have similarities. If anything, LIVE-AIR was a superset of ACTIV-5, with dex being left out of the latter. ACTIV-5 may keep running so that they can gather more data on Lenz + remdesivir specifically (if I remember correctly, in the LIVE-AIR results, Lenz + remdesivir and dex was not significantly better than Lenz + remdesivir alone), but I think there's something to the point Don brought up.
That is a very interesting point. Can a double blind trial for a drug take place if the same drug already has an EUA for the same indications?
On the NIH webcast, they said ACTIV-5 was small study looking for a big effect with the intent of moving the promising candidates to a bigger study under ACTIV-3. So look for Lenz to be moved to ACTIV-3 soon.
I'm on the road and haven't listed to yesterday's conference yet. According to someone on Twitter, Dr. Durrant said the CAR-T Ph2 study would begin in early 2022 with results expected in mid 2023. Can anybody confirm?
Any thoughts on how soon a BARDA order could come after EUA approval?
"we believe Chime will be able supply commercial product H1 2022"
2022? They will not be able to get production up this year?
"There will be basically zero demand in the states for an drug like Lenz for COVID by the end of summer."
Surveys say half of all Republicans will refuse the vaccine. That means max 75% of people in USA will be vaccinated. Covid may be suppressed through the summer by warmer temperatures, but I expect it to return next winter - perhaps even sooner, as people become complacent and stop masking.
I think it's very likely that Lenz will be 10k a dose in the USA. I agree the price could be lower in the EU and elsewhere since the USA pays the most of any country for health care. In poor countries, I would not be surprised to see a large reduction in the price.
Globally, it will take until at least 2023 before everyone that wants to receive the vaccine can get it.
In addition, the AstraZenica vaccine is used in many countries and that vaccine is much less effective against the Indian variants that are rapidly becoming more common. The Chinese vaccine is even worse in efficacy.
Yeah, the only thing I can think of for all the shorting is that they don't know how big Lenz is going to be.
Tether shows up as tradable on Coinbase for me under symbol $USDT.
Was able to snag some more $ETH at 2k.
Me too. Also adding some $ETH on this sell-off.
“All the experimental medicines, be plasma therapy (which is now discontinued) or Remdesivir, all of them may be dropped soon as there is no such evidence of its functioning. Right now only three medicines are working”, Dr. Rana said.
Too bad he didn't say which 3 medicines work.
Did the medRxiv preprint have any info regarding the outcome of the secondary endpoints?
Thanks. I have accounts at Coinbase and Voyager. Voyager is good, aside from scaling/growth issues, but I would like more access to altcoins. I did open an account at Kraken, but never funded it due to my bank giving me grief about wiring funds to a crypto exchange. That's when I signed up with Voyager, which uses ACH funding, instead.
I assume you use multiple crypto brokers/exchanges. Which ones do you use or recommend?
I don't know about you, but I find it gut-wrenching when I see videos of people in India pleading for help for themselves or their loved ones, people lying on the pavement outside hospitals because the beds are all full, people transporting the bodies of their deceased family members because ambulances are unavailable or they can't afford the cost of an ambulance, and funeral pyres packed into in parking lots that have been converted into crematoriums. If anything, the situation is much worse than the official numbers, perhaps 10x worse.
Agree with you 100%
And this is his first foray out of BP into small biotech. Quite a departure for him.
There are 12 postings like this on LinkedIn for different locations nationwide. The postings are 2 to 3 weeks old. It's positive news anyway. Good find!